Trial Condition(s):
Contrast medium
Study on the risk of allergy-like reactions after intra-arterial or intra-venous injection of the marketed X-ray contrast medium Iopromid (UVIA)
Bayer Identifier:
19677
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients. It is known that Iopromide may cause allergy-like reactions after being injected. With this study researchers want to find out, if the risk of severe allergy-like reactions is lower, when Iopromide will be injected into an artery, compared to the risk after an injection of Iopromid into a vein. To find this out data from four trials on Iopromide that are already completed will be combined and newly analyzed. The database used for this analysis will contain data from more than 150,000 patients.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many Locations Many Locations, Germany | Contact Us: E-mail: [email protected] Phone: (+)1-888-8422937 |
Trial Design
Risk of anaphylactoid reactions of Iopromide after intra-arterial administration
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Number of patients with anaphylactoid reactions of Iopromide after administrationTimeframe: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
Secondary Outcome
- Number of patients with anaphylactoid reactions after intra-arterial administration of IopromideTimeframe: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
- Number of patients with anaphylactoid reactions after intra-venous administration of IopromideTimeframe: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
Additional Information
Not Available
Copyright © Bayer
Powered by
